By Jason Derry —

Targeted Genetics Corp. has announced a non-exclusive licensing deal with Amsterdam Molecular Therapeutics B.V. relating to the use of the AAV1 (Adeno-Associated Virus
Type 1) vector.  The licensed AAV1 vector
is covered by U.S. Patent Nos. 6,759,237 and 7,105,345.  AMT intends to use the vector for developing
therapeutics for treating type I and type V lipoprotein lipase (LPL) deficiency.  In particular, AMT will use
the vector in the development of its lead gene product, AMT-011, which is in
Phase II clinical trials.  AMT and
Targeted Genetics are both focused on developing gene therapies for a variety
of diseases.

Jason Derry, Ph.D., who graduated with honors from DePaul University
College of Law, is a molecular biologist and founding author of Patent Docs.